Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Market, 2025-2033: Insights by Service, Product, End-Use and Region - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Inhaled Drugs Contract Manufacturing Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering.

The global inhaled drugs contract manufacturing market is experiencing significant growth, with its size projected to increase from USD 5.47 billion in 2024 to USD 12.56 billion by 2033. The market is set to grow at a compound annual growth rate (CAGR) of 9.82% from 2025 to 2033. This expansion is primarily driven by an increasing prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The demand for effective and targeted therapeutic options is consequently rising.

The heightened clinical need, along with the adoption of advanced inhalation therapies, is prompting pharmaceutical and biopharmaceutical companies to outsource drug development and manufacturing to specialized contract manufacturers. This strategic outsourcing is crucial to the growth of the inhaled drugs contract manufacturing industry.

As the patient population struggling with chronic respiratory conditions like asthma and COPD continues to grow, the demand for effective inhalation therapies-including dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers-is accelerating. The development of these therapies demands specialized expertise in areas such as formulation, particle size optimization, and device compatibility. Consequently, pharmaceutical companies are forming partnerships with contract manufacturing organizations (CMOs) to leverage their advanced infrastructure and regulatory experience. This collaboration supports faster development timelines and reduces capital expenditure, thus bolstering the market expansion.

The need for cost optimization and operational efficiency is further propelling the demand for contract manufacturing services. High capital investments are required for inhaled drug manufacturing, involving device integration, cleanroom facilities, and aerosol testing. Outsourcing to CDMOs, which possess comprehensive capabilities, allows drug developers to lessen capital expenditure while hastening time-to-market. Outsourcing also enables pharmaceutical companies to concentrate on their core competencies like research and marketing, while contract manufacturers secure long-term partnerships and steady production contracts, contributing to sustained market growth.

Global Inhaled Drugs Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at various levels and provides a thorough analysis of the latest industry trends from 2021 to 2033, segmented by service, product, end-use, and region:

Service Outlook (Revenue, USD Million, 2021-2033)

• Clinical Manufacturing
• Commercial Manufacturing
• Packaging & Labeling
• Others

Product Outlook (Revenue, USD Million, 2021-2033)

• Active Pharmaceutical Ingredient (API)
• Finished Drug Service
• Metered-dose inhalers (MDIs)
• Dry Powder Inhalers
• Nebulizers
• Others

End-use Outlook (Revenue, USD Million, 2021-2033)

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Medical Device Companies

Regional Outlook (Revenue, USD Million, 2021-2033)

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

Why You Should Buy This Report

• Comprehensive Market Analysis: Detailed insights into the market across major regions and segments.
• Competitive Landscape: Market presence of key players explored.
• Future Trends: Discover pivotal trends shaping the future of the market.
• Actionable Recommendations: Insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

• Market intelligence for effective decision-making
• Market estimates and forecasts from 2018 to 2030
• Growth opportunities and trend analyses
• Segment and regional revenue forecasts for market assessment
• Competition strategy and market share analysis
• Product innovation listings to stay ahead of the curve

Key Attributes

Report Attribute	Details
No. of Pages	150
Forecast Period	2024-2033
Estimated Market Value (USD) in 2024	$5.47 Billion
Forecasted Market Value (USD) by 2033	$12.56 Billion
Compound Annual Growth Rate	9.8%
Regions Covered	Global

The companies profiled in this Inhaled Drugs Contract Manufacturing market report include:

• Lonza Group
• Catalent Inc.
• Recipharm AB
• Hovione
• Kindeva Drug Delivery
• AptarGroup Inc.
• Vectura Group Ltd.
• Siegfried Holding AG
• CordenPharma
• PCI Pharma Services

For more information about this report visit https://www.researchandmarkets.com/r/2onj6z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.